12 High Yield Fortune 500 Stocks to Buy Now

9. Amgen Inc. (NASDAQ:AMGN)

Dividend Yield as of June 11: 2.85% 

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers innovative medicines to fight some of the world’s toughest diseases.

On June 10, Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen Inc. (NASDAQ:AMGN) from $322 to $340, while keeping an ‘Equal Weight’ rating on the shares. The boosted price goal still indicates a downside of over 4% from the current levels.

The US Food and Drug Administration (FDA) approved Amgen’s Uplizna as the first treatment for adults living with Immunoglobulin G4-related disease (IgG4-RD) last year.  The drug was later also approved by the European Commission as an add-on treatment to standard therapy for adults living with generalized myasthenia gravis (gMG) in February 2026.

Morgan Stanley noted that the launch of Uplizna for generalized myasthenia gravis (gMG) is “off to a strong start”. The firm believes that the gMG market has the potential to double to over $10 billion over the next five or so years, fueled by the introduction of new therapies and the rising adoption of biologics.

1281292 - 11759070 - 1